March 11 (Reuters) - Regenxbio said on Wednesday that interim data from a early-to-mid stage study of its experimental gene therapy in patients with Duchenne muscular dystrophy showed continued ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...

SGT-003 in the INSPIRE DUCHENNE trial to date - - Robust microdystrophin expression with consistent mechanistic evidence of dystrophin associated protein complex (DAPC) restoration and improvements in ...

People with BMD who received sevasemten in clinical trials maintained stable motor function over several years of follow-up, new data show.

Precision BioSciences Inc. (NASDAQ:DTIL) presented new preclinical findings for its PBGENE-DMD gene therapy at the Muscular ...

Detailed price information for Dyne Therapeutics Inc (DYN-Q) from The Globe and Mail including charting and trades.

The MESA data show stabilization of function in participants on sevasemten versus the predicted functional decline observed in Becker natural history ...

A new 3D model shows that Duchenne gene therapy can repair muscle fibers but fails to shut down the signals that drive scarring.

Solid Biosciences Inc. shares dropped more than 8% on Wednesday after the company released data from its Duchenne gene therapy trial. Trading in the stock was briefly halted earlier in the day. The ...

Market discussion surrounding the company aligns with broader sentiment linked to the nasdaq composite.

"Fast Track designation is an important regulatory milestone for PBGENE-DMD and reflects the significant unmet need in DMD," said Michael Amoroso, Chief Executive Officer of Precision BioSciences. "We ...

New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history - - Data expand on previously reported results demonstrating that z-ros ...